Clinical Trial Update: Efficacy and Safety of Ambrisentan in Children 8-18yrs [Phase 2]

View source ↗

Summary

Phase 2 trial update on ambrisentan in children aged 8-18 assessing efficacy and safety; study terminated with results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hypertension
• Pulmonary Hypertension

Drugs mentioned

• Ambrisentan (Ambrisentan)

Snippet

Sponsor: GlaxoSmithKline | Conditions: Hypertension, Pulmonary | Phase 2 | Status: TERMINATED | Results posted: 2019-10-08